Phathom Pharmaceuticals (PHAT) Current Deferred Revenue (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Current Deferred Revenue for 4 consecutive years, with $37.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Current Deferred Revenue rose 73.2% year-over-year to $37.3 million; the TTM figure through Jun 2026 stood at $37.3 million (up 73.2% YoY), while the FY2025 annual figure was $27.2 million, up 37.78% from the prior year.
• Current Deferred Revenue advanced to $37.3 million in Q2 2026 per PHAT's latest filing, from $33.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $37.3 million in Q2 2026 and bottomed at $276000.0 in Q2 2023.
• Historically, Current Deferred Revenue has averaged $18.2 million across 4 years, with a median of $19.8 million in 2024.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue jumped 3490.58% — and 2025, when it increased 4.79%.
• Phathom Pharmaceuticals' Current Deferred Revenue stood at $7.1 million in 2023, then surged by 178.12% to $19.8 million in 2024, then soared by 37.78% to $27.2 million in 2025, then jumped by 36.82% to $37.3 million in 2026.
• Business Quant data shows PHAT's Current Deferred Revenue at $37.3 million in Q2 2026, $33.0 million in Q1 2026, and $27.2 million in Q4 2025.